600222 Henan Taloph Pharmaceutical Stock
- 5.04
- +0.03+0.60%
Henan Taloph Pharmaceutical Stock News
Tailong Pharmaceutical (600222.SH) announced first-quarter results, net profit of 21.26 million yuan, an increase of 477.28% year-on-year
Tailong Pharmaceutical (600222.SH) disclosed its report for the first quarter of 2024. The company achieved revenue of 4.9 during the reporting period...
Investors Shouldn't Be Too Comfortable With Henan Taloph Pharmaceutical StockLtd's (SHSE:600222) Earnings
Henan Taloph Pharmaceutical Stock Co.,Ltd's (SHSE:600222) robust earnings report didn't manage to move the market for its stock. We did some digging, and we found some concerning factors in the detai
Tailong Pharmaceutical (600222.SH): The company did not implement share repurchases in March
Gelonghui, April 1, 丨 Tailong Pharmaceutical (600222.SH) announced that in March 2024, the company did not implement a share repurchase. As of March 31, 2024, the company has repurchased 1,205,200 shares, accounting for 0.21% of the company's total share capital. The highest price of the repurchase transaction was 4.32 yuan/share, the lowest price was 3.82 yuan/share, and the total amount paid was 4,955,198.00 yuan (excluding transaction fees).
Tailong Pharmaceutical (600222.SH) announced its 2023 annual results, with a net profit of 43.56 million yuan, turning a year-on-year loss into a profit
Tailong Pharmaceutical (600222.SH) disclosed its 2023 annual report, and the company achieved revenue of 20 in 2023...
Tailong Pharmaceutical (600222.SH): cumulative repurchase of 1.02 million shares
Gelonghui, March 1, 丨 Tailong Pharmaceutical (600222.SH) announced that as of February 29, 2024, the company had repurchased 1,205,200 shares through centralized bidding transactions, accounting for 0.21% of the company's total share capital. The highest price of the repurchase transaction was 4.32 yuan/share, the lowest price was 3.82 yuan/share, and the total amount paid was 4,955,198.00 yuan (excluding transaction fees).
Why Investors Shouldn't Be Surprised By Henan Taloph Pharmaceutical Stock Co.,Ltd's (SHSE:600222) 30% Share Price Plunge
To the annoyance of some shareholders, Henan Taloph Pharmaceutical Stock Co.,Ltd (SHSE:600222) shares are down a considerable 30% in the last month, which continues a horrid run for the company. In
Tailong Pharmaceutical (600222.SH): Initial repurchase of 688,300 shares
Gelonghui, Feb. 5 | Tailong Pharmaceutical (600222.SH) announced that on February 5, 2024, the company repurchased 688,300 shares for the first time through centralized bidding. The repurchased shares accounted for 0.12% of the company's total share capital. The highest transaction price was 4.32 yuan/share, the lowest price was 4.24 yuan/share, the average price was 4.25 yuan/share, and the total amount paid was 2,921,916.00 yuan (not including transaction fees such as trading commissions).
Tailong Pharmaceutical (600222.SH): “Tongjuntang” brand recognized as an old Chinese brand
Gelonghui, Feb. 1: Tailong Pharmaceutical (600222.SH) announced on the Ministry of Commerce website that according to the “Notice of 5 Departments Including the Ministry of Commerce on Announcing the Third Batch of Time-honored Chinese Brands”, the “Tongjuntang” brand of Tongjuntang Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, was successfully recognized as the third batch of time-honored Chinese brands by the Ministry of Commerce, the Ministry of Culture and Tourism, the General Administration of Market Supervision, the State Intellectual Property Office, and the State Administration of Cultural Heritage.
Tailong Pharmaceutical (600222.SH): Net profit pre-profit of 38 million yuan to 46 million yuan in 2023
Gelonghui, January 29丨Tailong Pharmaceutical (600222.SH) announced the 2023 annual performance pre-profit announcement. According to preliminary estimates by the company's finance department, it is estimated that net profit attributable to the owner of the parent company in 2023 will be 38 million yuan to 46 million yuan. Compared with the same period last year (legally disclosed data), it will turn a loss into a profit. It is estimated that net profit attributable to the owners of the parent company after deducting non-recurring profit and loss will be between RMB 30 million and RMB 38 million in 2023.
Tailong Pharmaceutical (600222.SH): Received 8.76 million yuan in government subsidies
Gelonghui, December 28, 丨 Tailong Pharmaceutical (600222.SH) announced that the company and its subsidiaries received a total of 8,764,146.77 yuan from October 1, 2023 to December 28, 2023, of which asset-related government subsidies amounted to 600,000 yuan, accounting for 0.04% of the company's most recent audited net assets attributable to shareholders of listed companies; 8,164,146.77 yuan in government subsidies related to earnings, accounting for 11.32% of the absolute value of the net profit attributable to shareholders of listed companies in the latest period.
Tailong Pharmaceutical (600222.SH): Plans to jointly transfer industry fund shares with related parties
Gelonghui, December 26丨Tailong Pharmaceutical (600222.SH) announced that Hangzhou Tailong Jintang Enterprise Management Co., Ltd., a wholly-owned subsidiary of the company, plans to transfer 0.67% of the Beijing-Hong Kong Fund's general partnership share of RMB 2.199,900; the Zhengzhou Longhua Pharmaceutical Industry Fund Partnership (Limited Partnership), which holds a total of 55% partnership share with the company's wholly-owned subsidiaries, intends to transfer 82.33% of the Beijing-Hong Kong Fund's limited partnership share for RMB 19.9653 million. After the transaction is completed, the executive partner and manager of the Beijing-Hong Kong Fund will be changed to Tibet Jinyuan Investment Management Co., Ltd.
Tailong Pharmaceutical (600222.SH): The company and subsidiaries have passed the re-certification of high-tech enterprises
Gelonghui (600222.SH) announced on December 19|Tailong Pharmaceutical () announced that according to the “Notice on the Filing of the First Batch of High-tech Enterprises” issued by the National High-tech Enterprise Accreditation Management Leading Group Office, it was learned that the company and its holding subsidiary, Beijing New Leading Pharmaceutical Technology Development Co., Ltd., a wholly-owned subsidiary of Beijing New Leading Pharmaceutical Technology Development Co., Ltd., have successfully passed the high-tech enterprise certification. This is a re-certification carried out by the company and the Zhengzhou Deep Blue Haiyuan High-tech Enterprise Certificate after its validity period expires.
Tailong Pharmaceutical (600222.SH): The company's product Habain is suitable for benign memory impairment
Gelonghui, December 18|Tailong Pharmaceutical (600222.SH) stated on the investor interactive platform that the company's product Habain (generic name: Huperzine tablets) is suitable for benign memory impairment, enhances patients' ability to point to memory, associative learning, image recall, meaningless graphics, and recall portraits, etc., and also has an effect on improving memory impairment caused by dementia patients and organic brain lesions. Please use it under the guidance of a pharmacist or refer to the drug instructions.
Tailong Pharmaceutical (600222.SH): Beijing Xinling, a holding subsidiary, mainly provides customers with pre-clinical pharmaceutical research and clinical CRO services
Gelonghui, December 12|Tailong Pharmaceutical (600222.SH) said on the investor interactive platform that Beijing Xinling, a holding subsidiary of the company, mainly provides customers with pre-clinical pharmaceutical research and clinical CRO services, and has rich experience in R&D services in high-end generic drugs and innovative drugs in cardiovascular, anti-tumor, and digestive system treatment fields.
Tailong Pharmaceutical (600222.SH): Controlling shareholder Tailong Industrial Investment proposed a share repurchase of 30 million yuan to 60 million yuan
On December 10, Gelonghui (600222.SH) announced that Tailong Pharmaceutical (), the controlling shareholder of the company, proposed to the board of directors that the company use its own capital to buy back some of the shares and use the repurchased shares for employee stock ownership plans or equity incentives at an appropriate time in the future. The repurchase amount is not less than RMB 30 million (inclusive) and no more than RMB 60 million (inclusive); the price of repurchase shares: no more than 150% of the average trading price of the company's stock in the first 60 trading days before the board of directors passes the repurchase decision.
Tailong Pharmaceutical (600222.SH): No antibiotics
Gelonghui November 28丨Tailong Pharmaceutical (600222.SH) stated on the investor interactive platform that the company has no antibiotics yet.
Tailong Pharmaceutical (600222.SH): Salvia salvia, a proprietary Chinese medicine product, has the effect of activating blood circulation and nourishing the heart
Gelonghui, November 22|Tailong Pharmaceutical (600222.SH) stated on the investor interactive platform that the company's proprietary Chinese medicine product salvia salvia oral liquid has the effects of activating blood circulation and nourishing the heart. Viburnum can nourish the heart, and nourish the stomach, and nourish the heart, all of which are drugs for the cardiovascular and cerebrovascular system.
Tailong Pharmaceutical (600222.SH): The controlling shareholder has not yet launched other major pharmaceutical and health management businesses
Gelonghui November 22|Tailong Pharmaceutical (600222.SH) stated on the investor interactive platform that the company's controlling shareholder has not yet carried out any other major pharmaceutical health business.
Tailong Pharmaceutical (600222.SH): The company's current daily production and operation activities are all normal
Gelonghui November 8 | Tailong Pharmaceutical (600222.SH) announced that the company's stock closed for three consecutive trading days on November 6, November 7, and November 8, 2023, with a cumulative deviation value of more than 20%. According to the relevant provisions of the “Shanghai Stock Exchange Trading Rules”, this is an abnormal fluctuation in stock trading. In the first three quarters of 2023, the company achieved operating income of 1,443 billion yuan, net profit attributable to shareholders of listed companies - 16.926,400 yuan, net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 23.875 million yuan, still remaining
Tailong Pharmaceutical (600222.SH): No cross-border export business involved
Gelonghui November 6 | Tailong Pharmaceutical (600222.SH) stated on the investor interactive platform that the company's products are mainly sold domestically and are not involved in cross-border export business for the time being.
Analysis
Price Target
No Data
